Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for ...

TELUS reports strong and industry leading operational and financial results for the fourth quarter and full year 2025; establishes compelling and industry-best 2026 financial ...

TELUS Corporation today released its unaudited results for the fourth quarter of 2025. Consolidated operating revenues and other income was $5.3 billion, compared with $5.4 billion in the prior year, ...

Warrior Reports Fourth Quarter and Full Year 2025 Results

Warrior Met Coal, Inc. (NYSE: HCC) ("Warrior" or the "Company") today announced results for the fourth quarter and full year 2025. Warrior delivered strong fourth-quarter and full-year results driven ...
pharmaphorum

One in five expressions of interest in UK regulator's pilot of real-world evidence scientific dialogue taken forward

The UK’s regulator, the MHRA, will be running five pilot dialogues as part of its first year exploring a real-world evidence scientific dialogue programme. The five were selected from 25 expressions ...

Cellebrite Announces Record Fourth-Quarter and Full-Year 2025 Results

Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced financial results for the three and twelve ...